Domestic DM combi drugs selected for market competitiveness

Donga Sugadapa (871 won → 799 won) & LG Zemidapa (1008 won → 940 won)

Expected to settle down in the first SGLT2i+DPP4i market

LG Chem and Dong-A ST are attracting attention by listing their DPP4i+SGLT2i combination as benefits, lowering the amount added.

 

It is interpreted as being conscious of price competitiveness.

 

According to the industry on the 22nd, Dong-A ST Sugadapa set the upper limit lower than the formula based on addition.

 

This drug is an improved new drug combination, so it was able to receive a drug price that combines 59.5% of the individual ingredients.

 

If there is no addition, you will receive the sum of 53.5% of the individual ingredients.

 

For example, 434 won, 59.5% of 730 won for Evogliptin 5mg and 393 won, 59.5% of 734 won for Dapagliflozin 10mg, was the amount Sugadapa could receive.

 

Dong-A ST decided to list it at 799 won, lower than the formula.

 

As a result, it became the product with the lowest upper limit than the SGTL2!+DPP4i complex, which was released first last month.

 

For the same reason, LG Chem's Zemidapa was also listed lower than the added amount.

 

Zemidapa was able to receive the sum of 68% of the individual ingredients as an innovative new drug complex.

 

The sum of 509 won, or 68% of 749 won for Gemigliptin 50mg and 499 won, or 68% of 734 won for Dapagliflozin 10mg, was able to receive 1,008 won.

 

Zemidapa was also listed at a lower price of 940 won.

 

However, even though the price of Zemidapa has been lowered, the upper limit is higher than that of competing drugs.

 

After one year, the price of the two drugs will drop to the sum of 53.55% of the individual ingredients.

 

Sugadapa is 784 won, and Zemidapa is 794 won.

 

In any case, this is because a lower addition than the existing formula was applied.

 

The low pricing of the two pharmaceutical companies is attracting attention in that they usually try to get a higher upper limit.

 

This can be interpreted as an intention to induce the market to settle down by lowering the price, as metformin + SGLT2i + DPP4i has been covered by reimbursement since April, and the SGLT2i + DPP4i combination was released for the first time in May.

 

Moreover, it seems to be aware of the competition as not only the two domestic products but also four other complexes were released.